The advanced glycation end-product (AGE) hypothesis proposes that accelerated chemical modification of proteins by glucose during hyperglycemia contributes to the pathogenesis of diabetic complications. The two most commonly measured AGEs, N ⑀ -(carboxymethyl)lysine and pentosidine, are glycoxidation products, formed from glucose by sequential glycation and autoxidation reactions. Although several compounds have been developed as AGE inhibitors and are being tested in animal models of diabetes and in clinical trials, the mechanism of action of these inhibitors is poorly understood. In general, they are thought to function as nucleophilic traps for reactive carbonyl intermediates in the formation of AGEs; however alternative mechanisms of actions, such as chelation, have not been rigorously examined. To distinguish between the carbonyl trapping and antioxidant activity of AGE inhibitors, we have measured the chelating activity of the inhibitors by determining the concentration required for 50% inhibition of the rate of copper-catalyzed autoxidation of ascorbic acid in phosphate buffer. All AGE inhibitors studied were chelators of copper, as measured by inhibition of metalcatalyzed autoxidation of ascorbate. Apparent binding constants for copper ranged from ϳ2 mM for aminoguanidine and pyridoxamine, to 10 -100 M for carnosine, phenazinediamine, OPB-9195 and tenilsetam. The AGE-breakers, phenacylthiazolium and phenacyldimethylthiazolium bromide, and their hydrolysis products, were among the most potent inhibitors of ascorbate oxidation. We conclude that, at millimolar concentrations of AGE inhibitors used in many in vitro studies, inhibition of AGE formation results primarily from the chelating or antioxidant activity of the AGE inhibitors, rather than their carbonyl trapping activity. Further, at therapeutic concentrations, the chelating activity of AGE inhibitors and AGE-breakers may contribute to their inhibition of AGE formation and protection against development of diabetic complications.
The Maillard or browning reaction between sugars and proteins leads to the formation of chemical modifications and cross-links in proteins, known as advanced glycation end-products (AGEs) 1 (1) . These products contribute to the age-dependent chemical modification of long lived tissue proteins (2) , and accelerated formation of AGEs during hyperglycemia is implicated in the development of diabetic complications (1, 2) . Consistent with the AGE hypothesis, AGE inhibitors, such as aminoguanidine (AG) (3) and pyridoxamine (PM) (4) , inhibit the formation of AGEs in various proteins in vitro and in collagen in vivo (5, 6) and retard the development of diabetic complications in animal models. The two most commonly measured AGEs, N ⑀ -(carboxymethyl)lysine (CML) and pentosidine, are glycoxidation products formed by sequential glycation and oxidation reactions (7) , and traces of transition metal ions in physiological buffers are potent catalysts of the formation of these AGEs in vitro (8) . AGE inhibitors are nucleophilic compounds designed to trap reactive carbonyl or dicarbonyl intermediates in AGE formation. However, as shown here, some of these compounds also have potent chelating activity, making it difficult to dissect the antioxidative, chelating activity from the carbonyl trapping activity of the inhibitors in in vitro studies. In the present work, we measured the chelating activity of AGE inhibitors by determining the concentration required for 50% inhibition of copper-catalyzed autoxidation of ascorbic acid in phosphate buffer. Using this assay, we show that AGE inhibitors have weak-to-potent metal chelating activity, and that, in fact, many experiments demonstrating the activity of AGE inhibitors in vitro are likely to be measuring the chelating activity rather than carbonyl trapping activity of these compounds. We also show that AGE-breakers and their hydrolysis products are potent chelators of copper and conclude that both the carbonyl trapping and chelation activity of AGE inhibitors and AGE-breakers may be involved in their therapeutic mechanism of action.
MATERIALS AND METHODS
Reagents-Unless otherwise noted, all chemicals were purchased from Sigma/Aldrich Chemical Co. Monobasic and dibasic sodium phosphate salts were purchased from EM Science (Gibbstown, NJ); heptafluorobutyric acid (HFBA) from Acros (Pittsburgh, PA), and nitric acid and HPLC grade acetonitrile from Fisher Scientific (Pittsburgh, PA). Tenilsetam ((Ϯ)-3-(2-thienyl)-2-piperazinone) (9, 10) was a gift from Aventis Pharma, Germany, and OPB-9195 ((Ϯ)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide) (11, 12) from Otsuka Pharmaceuticals, Japan. Phenacylthiazolium bromide (PTB) and phenacyldimethylthiazolium bromide (PMTB) were synthesized according to the methods of Vasan et al. (13) and Wolfenbü ttel et al. (14) , respectively, and purified to homogeneity by reverse-phase HPLC. 2,3-Diaminophenzine (DAP) was synthesized according to Soulis et al. (15) . PTB, PMTB, and DAP were homogeneous by reverse phase-HPLC analysis and by electrospray ionization liquid chromatography-mass spectrometry. All water used in these experiments was distilled and then deionized (15-18 M⍀) using a mixed bed ion-exchanger with activated charcoal polisher. Chelex-100 (ϳ80% water content) was sus-pended and allowed to settle several times in water to remove soluble chelator and fine particles (16) . To remove metal ions from phosphate buffer, chelex-100 resin (7 g/liter, wet weight) was added to 50 mM phosphate buffer, pH 7.4, in a 2-liter plastic container and rocked gently overnight at room temperature. The buffer was stored at room temperature in the same container, allowing the resin to settle to the bottom; aliquots were removed for experiments, as needed.
Measurement of the Kinetics of Oxidation of Ascorbic Acid-All incubations (1.5-ml total volume) were conducted in chelex-treated 50 mM phosphate buffer, pH 7.4, in a water bath at 30°C; reagents were pre-equilibrated at this temperature for at least 5 min. In preliminary experiments, the kinetics of oxidation of AA was determined in quartz spectrophotometer cuvettes by measuring the rate of decrease in absorbance at 265 nm, as described by Buettner (17) ; the cuvettes were precleaned by soaking overnight in 1% nitric acid. AA (500 M) was stable (Ͼ99% recovery) in chelex-treated 50 mM phosphate buffer, pH 7.4, for at least 1 h. Addition of 500 nM CuCl 2 yielded a half-life of approximately 1 h.
For studies with AGE inhibitors, the copper and inhibitor were preincubated in phosphate buffer for 5 min, and then the ascorbate was added from a concentrated solution (75 l of 10 mM AA in water) to initiate the reaction. Aliquots (150 l) were removed at 0, 15, 30, 45, and 60 min and transferred to autoinjector vials containing 15 l of 10 mM diethylenetriaminepentaacetic acid (DTPA) to quench the metalcatalyzed oxidation reaction. Samples were analyzed by RP-HPLC, using a Supelcosil LC-18 column (25 cm ϫ 4.6 mm, 5 m) (Supelco; Bellefonte, PA) on a Shimadzu (Columbia, MD) LC-10Ai liquid chromatograph equipped with a SIL-10Ai auto-injector and an SPD-10AV UV-Vis detector. Solvents for HPLC were: A, 0.1% HFBA in water and B, 50% acetonitrile. The gradient was 100% A at 0 min, increase to 80% B from 0 to 4 min, return to 100% A from 4 to 4.1 min, then reequilibrate in 100% A from 4.1 to 9 min. The absorbance of ascorbic acid was measured at 244 nm (Fig. 1) , and the peak area was integrated to estimate the percent of AA remaining versus time. The equations for the least-squares fits to these plots (triplicate analyses) were determined with SigmaPlot 2000 (Jandel Scientific) and used to determine the concentration of each compound that inhibited the rate of AA oxidation by 50% (IC 50 ).
RESULTS
All assays with AGE inhibitors were performed in triplicate by HPLC, measuring residual ascorbate by absorbance at 244 nm ( Fig. 1) . None of the compounds tested co-eluted with or otherwise interfered with the measurement of ascorbate by this RP-HPLC method. In preliminary studies, we adjusted experimental conditions to obtain a concentration of cupric ion that would catalyze the oxidation of AA (500 M) with an approximate half-life of 1 h. As shown in Fig. 2 (lower lines; without AG or PM), this was achieved by addition of 500 nM CuCl 2 to 50 mM chelex-treated phosphate buffer, pH 7.4, at 30°C. This half-life was comparable with the half-life of ascorbate in 0.1 M phosphate buffers prepared in our laboratory; however, buffers prepared with different batches of phosphate salts varied in their catalytic activity because of batch-to-batch variation in metal ion content.
The AGE inhibitors, AG and PM, inhibited the oxidation of AA in a concentration-dependent manner (Fig. 2) . The linearity of the semilogarithmic plots illustrates that the AGE inhibitors did not alter the pseudo-first order kinetics of the autoxidation reaction. Graphical analysis of the rate of ascorbate oxidation versus inhibitor concentration indicated that percent inhibition was not a linear function of inhibitor concentration. The linear relationships between percent inhibition and the square of the inhibitor concentration, shown in Fig. 3 , were consistent with formation of 2:1 or higher valency complexes between AG or PM and Cu(II) ions. These data yielded IC 50 values of ϳ2.5 mM for AG and ϳ1 mM for PM. Amine nitrogens are common ligands for transition metal ions and pyridoxine (IC 50 ϳ3.6 mM) and pyridoxal (IC 50 Ͼ Ͼ 5 mM), with a hydroxymethyl or carboxaldehyde group, in lieu of the aminomethyl group of PM, were less inhibitory than PM itself (Fig. 3) .
Carnosine and its the constituent amino acid histidine were potent inhibitors of AA oxidation, with IC 50 values ϳ4 and 12 M, respectively (Fig. 4A) . The antioxidative effect of carnosine and histidine was an asymptotic function of increasing inhibitor concentration, suggesting that the chelate species may have some residual catalytic activity. Among other compounds tested, taurine and ethanol had no effect on metal-catalyzed oxidation of AA. As shown in Fig. 4B , the AGE inhibitors, DAP and tenilsetam, had IC 50 values of ϳ50 and 25 M, respectively, whereas OPB-9195 (Fig. 4C ) yielded a consistently non-linear response with a minimum at ϳ5 M.
Both of the AGE-breakers, PTB and PMTB, were also potent inhibitors of ascorbate oxidation, with IC 50 values of ϳ10 and 80 M, respectively (Fig. 5) . Because the half-life of PTB and PMTB were 2 and 8 h, respectively, in phosphate buffer at 30°C, 2 we also measured the activity of the hydrolysis products in the ascorbate oxidation system. For these experiments, the AGE-breakers were incubated for 24 h in buffer prior to addition of the ascorbate. As also shown in Fig. 5 , the hydrolysis products had IC 50 values of Ͻ2 M and were among the most potent inhibitors of metal-catalyzed oxidation of ascorbate. The non-linear response obtained with native PTB (Fig. 5A ) suggests that ongoing hydrolysis, ϳ30% during the course of the 1-h incubation, may have contributed to the increased inhibitory activity of this compound at higher concentrations.
To assess the potential role of AGE inhibitors and AGEbreakers as inhibitors of metal-catalyzed oxidation chemistry in vivo, we also measured the effects of plasma albumin on the kinetics of ascorbate oxidation. As shown in Fig. 6 , among all the compounds tested, bovine serum albumin was the most potent inhibitor of ascorbate oxidation on a molar basis. The IC 50 for bovine serum albumin, ϳ80 nM (ϳ5 g/ml), was 16% of the concentration of Cu(II) in the reaction system, suggesting at least 6 binding sites for copper.
DISCUSSION
Chelation Activity of AGE Inhibitors-The late Simon Wolff was a pioneer in focusing attention on the metal chelating activity of drugs designed for other activities (18, 19) . Aldose reductase inhibitors and anti-inflammatory agents with anticataract activity were shown to have substantial chelating activity, suggesting that their chelating activity might protect lens proteins from chemical damage by inhibiting metal-catalyzed autoxidation of sugars or ascorbate (20, 21) . In the present study we have evaluated the chelating activity of various AGE inhibitors to determine the role of metal chelation in the mechanism of action of AGE inhibitors. A typical reaction pathway for the formation of AGEs from AA (and other carbohydrates) in vitro is shown in Fig. 7 . Metal-catalyzed autoxidation chemistry accelerates the browning and cross-linking of protein by carbohydrates and is essential for the formation of the glycoxidation products, CML and pentosidine. Chelators such as DTPA are potent inhibitors of formation of these AGEs from ascorbate (22) and glucose (23) (Fig. 7, dotted arrows) . In contrast, AGE inhibitors, such as AG and PM, are thought to function as carbonyl traps (3, 4) , reacting with electrophilic, 
FIG. 5. Effect of AGE-breakers and their hydrolysis products on the kinetics of copper-catalyzed oxidation of ascorbic acid.
A, PTB (OE) and PTB hydrolysis products (‚) generated by incubation in phosphate buffer for 24 h. B, PMTB (q) and PMTB hydrolysis products (E) generated by incubation in phosphate buffer for 24 h. carbonyl intermediates formed on autoxidation of carbohydrates, thereby protecting against chemical modification of nucleophilic residues on protein (Fig. 7, solid arrow) . Our experiments show, however, that AGE inhibitors are also transition metal chelators and inhibit the autoxidation of ascorbate, prior to formation of reactive carbonyl compounds. AGE inhibitors had IC 50 values for copper ranging from the millimolar range for AG and PM to micromolar values for carnosine, tenilsetam, DAP, and OPB-9195. These results indicate that AGE inhibitors have two mechanisms of action in vitro: first, inhibition of formation of reactive carbonyl intermediates; and second, nucleophilic reaction with these intermediates.
AGE Inhibitors in Vitro-High concentrations of AG and other inhibitors have been employed in many studies, including our own (23) (24) (25) (26) , on the mechanism of action of AGE inhibitors. These high inhibitor concentrations have been justified because of the high concentrations of glucose used to accelerate AGE formation in in vitro reactions. Based on the present work, however, it is more likely that AG, at concentrations in the 5-25 mM range, i.e. 2-10-fold higher than its IC 50 , exerts its primary effect by inhibiting autoxidation chemistry; this inhibition is observed not only with the copper-supplemented chelex-treated phosphate buffers used in our experiments, but also with commercial phosphate buffers containing traces of mixed metal ions. Similar results were obtained for AG and PM in the presence of iron salts, although iron was about 10-fold less effective as a catalyst of ascorbate autoxidation reactions at neutral pH. Other AGE inhibitors, such as carnosine, DAP, tenilsetam, and OPB-9195, which have much stronger metal binding activity (Table I) , are likely to act primarily as chelators at the millimolar concentrations commonly employed for these reagents in vitro. Chelation may, therefore, confound the identification of AGE inhibitors, e.g. in two recent studies in which a large number of heterocyclic AGE inhibitors were described (27, 28) but are more likely to inhibit AGE formation through their chelation, rather than carbonyl trapping activity. For AG and PM, however, triazines (29) and amides (30) have been identified as discrete adducts to carbonyl compounds during glycoxidation and lipoxidation reactions, confirming that, in addition to their chelating activity, they also act as true scavengers of carbonyl compounds. Similar experiments will have to be performed with other AGE inhibitors to confirm their proposed mechanism of action as carbonyl traps.
The estimate of the IC 50 for inhibition of ascorbate oxidation is a useful, but comparative measure of the chelation activity of AGE inhibitors. It is the empirical result of equilibrium constants for metal binding by the multiple species of ascorbate (31) , the AGE inhibitor and the phosphate buffer ions in solution, rather than an actual K d for the AGE inhibitor-metal complex. In most cases, except for pyridoxamine (32) and carnosine (33), true metal binding constants have not been measured. Because of the complexity of the equilibria involved, the IC 50 for an AGE inhibitor will vary with buffer, metal ion, and ascorbate concentration, and even with the specific sugar under study, e.g. glucose, which exists to a lesser extent in the enolate conformation, would bind transition metal ions more weakly than ascorbate. Variations in the species and concentrations of metal ion contaminants in buffers will also affect the apparent IC 50 for specific inhibitors, depending on their respective binding constants with AGE inhibitors.
How can one avoid the complex and confounding effects of chelation in studies on AGE inhibitors? One solution is to conduct these studies in the presence of a strong chelator, such as DTPA, so that the contribution of the AGE inhibitor to chelation would be minimal. However, DTPA itself is a potent inhibitor (Ͼ99% at 1 mM (23)) of AGE formation from glucose and ascorbate, so that reaction times would be excessive, even at high glucose concentration. We suggest that it may be best to evaluate the efficacy of AGE inhibitors by studying the browning of proteins by pentoses. Pentoses are 10 -100 times more reactive than glucose with protein, so that lower concentrations of sugar can be used. Glycation of protein by pentoses also leads to formation of AGEs, cross-links and fluorescence characteristic of the modification of protein by glucose (34) . Importantly, Maillard reactions of pentoses proceed readily under nitrogen and in the presence of chelators (35) . Experiments on the browning of proteins by pentoses can be conducted in the presence of strong chelator such as DTPA, so that the chelating activity of the inhibitor would not affect the kinetics of AGE formation in pentose model systems.
AGE Inhibitors in Vivo-The significance of the chelating activity of AGE inhibitors in vivo is difficult to assess, consid- b After a 24-h incubation in metal-free phosphate buffer.
ering the powerful inhibition of ascorbate oxidation observed with albumin (Fig. 6 ). Yet, albumin is subject to metal-catalyzed oxidation and formation of Maillard products from glucose in vitro, and AGEs are present on albumin in vivo (36) . It is likely that metals bound to albumin are in equilibrium with metals bound to other proteins, and protein-bound metal ions, even when bound to proteins such as albumin (37) or low density lipoprotein (38) , may remain redox-active and induce site-specific cleavage of the proteins in the presence of peroxide (39) . Despite lower binding constants, compared with albumin and chelators such as DTPA, AGE inhibitors may gradually deplete excess chelatable iron in the body by promoting the excretion of metal ion complexes in urine. Even a weak chelator, such as AG or PM, which might not inhibit autoxidation reactions significantly at therapeutic concentrations (Ͻ100 M), could promote the gradual removal of free metal ions from tissues and plasma for excretion in urine, decreasing overall metal-catalyzed oxidative damage to proteins in vivo. Monnier and Eaton and co-workers (40, 41) have proposed that AGEs on proteins may serve to bind redox-active, transition metal ions, enhancing local oxidative damage to proteins. If AGE inhibitors remove weakly bound metal ions from these "glycochelates," they may both inhibit AGE formation (by chelation and/or carbonyl trapping) and also reduce other metal-catalyzed oxidative damage to tissues resulting from the presence of AGEs. Measurements of chelatable iron and copper in control versus AGE inhibitor-treated animals should clarify the therapeutic significance of the weak chelating activity of AGE inhibitors. Notably, although chelators are not used clinically for the treatment of diabetic complications, chelators have recently proven effective in treatment of vascular disease (42) and neuropathy (43) in the STZ-diabetic rat. AGE inhibitors vary widely in their IC 50 values in the ascorbate model system, from the millimolar range for AG and PM, to the micromolar range for carnosine, DAP, tenilsetam, and OPB-9195. At plasma concentrations of Ͻ100 M, i.e. Ͻ10% of their IC 50, both AG and PM were effective in inhibiting the formation of AGEs and development of complications in animal models of diabetes (5) . Among the stronger chelators, the concentration of carnosine in tissues (up to 20 mM) (44) far exceeds its IC 50 , while the therapeutic concentration of tenilsetam, ϳ10 M (45), is comparable with its IC 50 in the ascorbate system (25 M; Fig. 4B ). The therapeutic concentrations of DAP and OPB-9195 have not been reported, but are probably also in the micromolar range, suggesting that chelation would contribute to their AGE inhibitory activity in vivo.
Chelating Activity of AGE-breakers-The AGE-breakers PTB and PMTB were among the most potent inhibitors of coppercatalyzed oxidation of ascorbate, and the hydrolysis products of these compounds exhibited even stronger chelating activity. Hydrolysis of PTB leads to opening of the thiazolium ring, producing a sulfhydryl compound (46) . Mercaptans are excellent ligands for copper and other transition metals, which might explain the strong chelating activity of the hydrolysis products of PTB and PMTB. Because PTB also protects Escherichia coli against MGO toxicity, almost as well as AG (47) , it is also possible that the hydrolysis products may have carbonyl trapping activity. The chelating properties of AGE-breakers is sufficiently strong that they may also have some lathyrogenic activity, inhibiting the enzymatic cross-linking of collagen, possibly leading to decreased cross-linking and greater elasticity of newly synthesized collagen.
Summary-We have shown that AGE inhibitors have significant copper chelating activity. While we have not studied other metals in detail, similar inhibitory effects were observable with phosphate buffers containing a mixture of trace metal ions. The general metal chelating activity of AGE-directed drugs containing nitrogen and thiol groups most certainly contributes to the chelating activity of putative AGE inhibitors in vitro and could be important in their mechanism of action in vivo. Screening assays for AGE inhibition should account for metal chelation by working with inhibitor concentrations below their IC 50 or by using pentoses as glycating agents. Identification and characterization of products trapped by the AGE inhibitors is also critical for confirming their mechanism of action. Defining the chelating versus carbonyl trapping activity of AGE inhibitors is essential for understanding the mechanism of action of these drugs and the possible benefits of chelation therapy in diabetes, and for developing more effective, clinically useful inhibitors of diabetic complications.
